908 Devices Inc. (NASDAQ:MASS) Receives Average Recommendation of “Buy” from Analysts

Shares of 908 Devices Inc. (NASDAQ:MASS) have been given a consensus recommendation of “Buy” by the four research firms that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $8.00.

MASS has been the topic of a number of analyst reports. Wall Street Zen raised 908 Devices from a “sell” rating to a “hold” rating in a research note on Monday, September 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of 908 Devices in a research note on Saturday, September 27th. Leerink Partners raised 908 Devices from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a research note on Tuesday, August 5th. Finally, Leerink Partnrs upgraded shares of 908 Devices from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 5th.

Insider Activity at 908 Devices

In related news, CFO Joseph H. Iv Griffith sold 5,000 shares of the company’s stock in a transaction on Friday, September 19th. The shares were sold at an average price of $7.07, for a total value of $35,350.00. Following the completion of the sale, the chief financial officer owned 97,930 shares in the company, valued at $692,365.10. This represents a 4.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 23.70% of the stock is currently owned by corporate insiders.

Institutional Trading of 908 Devices

A number of large investors have recently made changes to their positions in MASS. Northern Trust Corp increased its position in shares of 908 Devices by 7.5% in the 4th quarter. Northern Trust Corp now owns 200,764 shares of the company’s stock valued at $442,000 after buying an additional 14,087 shares in the last quarter. Jane Street Group LLC raised its stake in shares of 908 Devices by 118.9% in the 4th quarter. Jane Street Group LLC now owns 113,890 shares of the company’s stock valued at $251,000 after purchasing an additional 61,851 shares during the period. Bank of America Corp DE raised its stake in shares of 908 Devices by 190.9% in the 4th quarter. Bank of America Corp DE now owns 94,753 shares of the company’s stock valued at $208,000 after purchasing an additional 62,179 shares during the period. Deutsche Bank AG raised its stake in shares of 908 Devices by 1,159.4% in the 4th quarter. Deutsche Bank AG now owns 99,239 shares of the company’s stock valued at $218,000 after purchasing an additional 91,359 shares during the period. Finally, Two Sigma Advisers LP acquired a new stake in shares of 908 Devices in the 4th quarter valued at about $30,000. Institutional investors own 88.06% of the company’s stock.

908 Devices Stock Performance

Shares of MASS opened at $8.75 on Friday. The business’s fifty day moving average price is $6.66 and its two-hundred day moving average price is $5.98. The firm has a market capitalization of $313.78 million, a price-to-earnings ratio of -16.20 and a beta of 0.46. 908 Devices has a 52 week low of $1.81 and a 52 week high of $9.09.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). The company had revenue of $4.70 million during the quarter, compared to analyst estimates of $12.17 million. 908 Devices had a negative net margin of 30.54% and a negative return on equity of 24.30%. 908 Devices has set its FY 2025 guidance at EPS. As a group, research analysts forecast that 908 Devices will post -1.99 EPS for the current year.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.